Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -

- Elegrobart, potentially the first subcutaneous autoinjector for the treatment of TED, on track for BLA submission Q1 2027 -

- Pipeline progress continues, with FcRn and TSHR program development milestones on track in 2026 -

- Completed convertible debt and equity financing in May 2026 with gross proceeds of $394 million; cash, cash equivalents, and marketable securities of $982 million as of June 30, 2026 -

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Other newsrooms on this story

Related reading

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For…

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™…

Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa

Viridian may have edge over Amgen in eye drug showdown, analysts argue

FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza

Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal